Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nishino, 2014, . State of the art: response assessment in lung cancer in the era of genomic medicine., Radiology, 271, 6, 10.1148/radiol.14122524
Nishino, 2011, . Imaging of lung cancer in the era of molecular medicine., Acad Radiol, 18, 424, 10.1016/j.acra.2010.10.020
Gazdar, 2009, Personalized medicine and inhibition of EGFR signaling in lung cancer., N Engl J Med, 361, 1018, 10.1056/NEJMe0905763
Lynch, 2004, . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib., N Engl J Med, 350, 2129, 10.1056/NEJMoa040938
Paez, 2004, . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy., Science, 304, 1497, 10.1126/science.1099314
Pao, 2004, . EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib., Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101
Maemondo, 2010, . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530
Usuda, 2014, Motono N, et al.., Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive Asian Pac J Cancer Prev, 15, 657
Mok, 2009, . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N Engl J Med, 361, 947, 10.1056/NEJMoa0810699
Rosell, 2012, . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X
Thunnissen, 2014, Prognostic and predictive biomarkers in lung cancer. A review., Virchows Arch, 464, 347, 10.1007/s00428-014-1535-4
Zhou, 2011, . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X
Sequist, 2008, . First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations., J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494
Haneda, 2006, . A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma., Jpn J Clin Oncol, 36, 69, 10.1093/jjco/hyi228
Lee, 2013, . Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes., Radiology, 268, 254, 10.1148/radiol.13112553
Choi, 2014, . Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy., Radiology, 270, 574, 10.1148/radiol.13121824
Onn, 2005, . Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome., Radiology, 237, 342, 10.1148/radiol.2371041650
Jung, 2013, Biopsy and mutation detection strategies in non-small cell lung cancer., Tuberc Respir Dis (Seoul), 75, 181, 10.4046/trd.2013.75.5.181
Togashi, 2011, . Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma., Cancer, 117, 819, 10.1002/cncr.25618
Obenauer, 2005, Applications and literature review of the BI-RADS classification., Eur Radiol, 15, 1027, 10.1007/s00330-004-2593-9
Khan, 2010, Allen CM, et al.., The calcified lung nodule: what does it mean Ann Thorac Med, 5, 67
Travis, 1995, Lung cancer., Cancer, 75, 191, 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
Auerbach, 1991, The changing pattern of lung carcinoma., Cancer, 68, 1973, 10.1002/1097-0142(19911101)68:9<1973::AID-CNCR2820680921>3.0.CO;2-Z
Lee, 2013, . Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis., J Natl Cancer Inst, 105, 595, 10.1093/jnci/djt072
Jackman, 2006, . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib., Clin Cancer Res, 12, 3908, 10.1158/1078-0432.CCR-06-0462
Zhu, 2008, . Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals., Cancer Lett, 265, 307, 10.1016/j.canlet.2008.02.064
Hsieh, 2005, . Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer., Chest, 128, 317, 10.1378/chest.128.1.317
Jang, 2009, . EGFR and KRAS mutations in patients with adenocarcinoma of the lung., Korean J Intern Med, 24, 48, 10.3904/kjim.2009.24.1.48
Tsao, 2006, . Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer., J Thorac Oncol, 1, 231, 10.1016/S1556-0864(15)31573-2
Travis, 2011, . International association for the study of lung canceramerican thoracic societyeuropean respiratory society international multidisciplinary classification of lung adenocarcinoma., J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221
Yanagawa, 2009, . One-dimensional quantitative evaluation of peripheral lung adenocarcinoma with or without ground-glass opacity on thin-section CT images using profile curves., Br J Radiol, 82, 532, 10.1259/bjr/70480730
Aoki, 2012, . Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers., Radiology, 264, 590, 10.1148/radiol.12111337